TLDR
- SELLAS stock jumps after hours as REGAL AML trial nears key readout
- SLS gains momentum as Phase 3 REGAL approaches pivotal AML data
- SELLAS advances SLS009 while REGAL trial nears 80-event trigger
- SLS stock surges after hours on key AML trial progress update
- SELLAS reports wider loss but keeps strong cash ahead of REGAL data
SELLAS Life Sciences Group (SLS) stock drew fresh attention after a sharp after-hours move followed its first-quarter update. SLS closed at $14.06, down 2.83%, before jumping 26.60% after hours to $17.80. The move came as the company moved closer to a key AML readout from its Phase 3 REGAL trial.
SELLAS Life Sciences Group, Inc., SLS
Phase 3 REGAL Trial Nears Key AML Readout
SELLAS said its Phase 3 REGAL trial has reached 78 deaths as of May 11, 2026. The trial needs 80 events before database lock, review, analysis, and topline data disclosure. As a result, the company now stands near a major clinical milestone.
The REGAL study evaluates GPS in acute myeloid leukemia patients in complete remission. These patients entered remission after second-line salvage therapy, which makes the trial clinically important. Therefore, the readout could shape the company’s late-stage oncology path.
SELLAS has built much of its near-term plan around the REGAL result. The company has also prepared for potential regulatory work tied to GPS. Besides, higher trial and manufacturing costs show that preparation moved forward during the quarter.
SLS009 Advances In Earlier-Line AML
SELLAS also advanced SLS009, known as tambiciclib, across AML clinical and preclinical work. The company has started dosing patients in an 80-patient Phase 2 study. The trial targets newly diagnosed AML patients, including those unlikely to benefit from standard therapy.
The company expects topline data from the SLS009 Phase 2 study in Q4 2026. The study includes patients who become refractory early to AZA and venetoclax treatment. Consequently, SELLAS aims to address hard-to-treat AML groups with limited options.
Recent AACR data added more background to the SLS009 program. The preclinical results showed apoptosis in AML cell lines with high-risk ASXL1 and TP53 mutations. Moreover, the drug reduced MCL-1 and survivin levels, which linked with stronger cancer cell death.
SELLAS Reports Wider Loss But Strong Cash Position
SELLAS reported research and development expenses of $5.1 million for the first quarter. That compared with $3.2 million in the same quarter last year. The increase came from manufacturing, clinical trial costs, and regulatory consulting tied to REGAL preparations.
General and administrative expenses also rose to $4.1 million in the quarter. That figure compared with $2.9 million in the first quarter of 2025. The rise reflected higher professional fees, consulting costs, public company expenses, and stock-based compensation.
SELLAS posted a net loss of $8.4 million, or $0.05 per share. The company held $107.1 million in cash and equivalents as of March 31. Additionally, it received $7.5 million after quarter-end from warrant exercises.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
